NICE and NHS England Oppose Sativex to Treat Spasticity in MS, Urge More Studies of Medical Cannabis

NICE and NHS England Oppose Sativex to Treat Spasticity in MS, Urge More Studies of Medical Cannabis

Publication date: Aug 12, 2019

This post was originally published on this site A draft guidance issued by the National Institute for Health and Care Excellence (NICE), a U. K. advisory board, and a review by England’s National Health Service (NHS) call for more research into medical cannabis for multiple sclerosis and other conditions. Eight separate recommendations for further research were made across all indications and products covered, which NICE said reflected an overall lack of evidence of clinical benefit and cost-effectiveness regarding these products. The guidance also recommends against using other options for the same purpose outside of a clinical trial because of -a lack of clear evidence that these treatments provide any benefits,” NICE states in its press release. Sativex and nabilone are the only cannabis-based medicines licensed for use by adults in the U. K., NICE notes in its draft guidance. The post NICE and NHS England Oppose Sativex to Treat Spasticity in MS, Urge More Studies of Medical Cannabis appeared first on Multiple Sclerosis News Today. The post NICE and NHS England Oppose Sativex to Treat Spasticity in MS, Urge More Studies of Medical Cannabis appeared first on BioNewsFeeds.

Concepts Keywords
Cannabidiol Drugs
Cannabis Medicine
Chemotherapy Health
Chronic Pain Chemotherapy
Clinical Trial MS
Clinical Trials Intractable nausea
England Nausea vomiting
Epilepsy Chronic pain plant
Medical Cannabis Vomiting
Multiple Sclerosis Resistant severe epilepsy
Muscle Medicinal products
Nausea Re classification products
NHS Unlicensed products
NHS England Medicinal cannabis products
NICE Cannabinoids
Pharmaceutical Appetite stimulants
Sativex Herbalism
Spasticity Medicinal plants
Stiffness Analgesics
Synthetic Cannabinoid Nabiximols
Vomiting Medical cannabis
Chemotherapy

Semantics

Type Source Name
gene UNIPROT NHS
drug DRUGBANK Medical Cannabis
gene UNIPROT DESI1
gene UNIPROT SLC35G1
gene UNIPROT CHL1
gene UNIPROT SET
gene UNIPROT CCN3
gene UNIPROT PLXNA1
drug DRUGBANK Methionine
gene UNIPROT SLTM
gene UNIPROT MET
disease MESH chronic pain
disease MESH epilepsy
disease DOID epilepsy
pathway BSID Release
drug DRUGBANK Cannabidiol
drug DRUGBANK Nabilone
drug DRUGBANK Isoxaflutole
gene UNIPROT CD69
gene UNIPROT DNMT1
gene UNIPROT BPIFA4P
disease MESH Multiple Sclerosis
disease DOID Multiple Sclerosis
drug DRUGBANK Nonoxynol-9

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *